ECOR Stock — Electrocore LLC

Electrocore LLC (ECOR)

Updated October 16, 2026.

ECOR is a Stock. Total return is -97.4% over the past 8.3 years, 312.0 points behind SPY at 214.6%.

electroCore, Inc. is a bioelectronic medicine company that develops non-invasive vagus nerve stimulation technology for treating migraine, cluster headache, and chronic pain conditions, along with consumer wellness products. The company does not currently have an established distribution program. The business may appeal to investors interested in healthcare innovation and medical device companies, though prospective investors should evaluate the company's path to profitability and clinical validation of its therapies.

ECOR performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.4% over the past 8.3 years, 312.0 points behind SPY at 214.6%. Over the past year its total return — price change plus distributions reinvested — is 56.4%. Its deepest 1-year drawdown was 44.2%.

ECOR key facts

Asset type

Stock

Asset class

Equity

Inception date

06/22/2018

Distribution frequency

None

Last close

$7.85 (as of 2026-10-16)

Market cap

$70,774,697

Average volume

141382.0

Beta

1.054

Payout ratio

0.0%

Forward P/E

384.6154

EPS

$-1.65

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ECOR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 44.2%.

Who may consider ECOR — and who may not

It is a weaker fit for investors who need monthly cash flow (ECOR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ECOR

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions